FDA Approves Curio Digital Therapeutics PDT For Postpartum Depression

On April 23, 2024, Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) granted clearance to MamaLift Plus, a prescription digital therapeutic (PDT) for treating mild-to-moderate postpartum depression. The PDT can be used on a mobile device and is intended as adjunct treatment for people aged 22 years and older who are receiving outpatient care supervised by a clinical professional. Curio intends to launch MamaLift Plus during the summer of 2024. It will be available for download in the iOS App Store and Android Play Store.

During the eight-week treatment period, MamaLift . . .